Charles River Laboratories International (NYSE:CRL) Hits New 52-Week High – What’s Next?

Charles River Laboratories International, Inc. (NYSE:CRL)’s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as $238.85 and last traded at $230.8780, with a volume of 70610 shares trading hands. The stock had previously closed at $218.70.

Wall Street Analyst Weigh In

Several research firms have commented on CRL. Mizuho raised their target price on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a report on Monday. Finally, Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Price Performance

The company has a market capitalization of $10.98 billion, a P/E ratio of -60.27, a PEG ratio of 2.44 and a beta of 1.40. The stock’s fifty day simple moving average is $195.88 and its 200-day simple moving average is $187.04. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after purchasing an additional 47,432 shares during the period. Invesco Ltd. boosted its stake in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. State Street Corp grew its holdings in Charles River Laboratories International by 2.2% during the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after acquiring an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after buying an additional 210,260 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Charles River Laboratories International by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after buying an additional 9,756 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.